TARGET-MELANOMA

Molecular Dissection of Melanoma Progression: An integrated Pan-European Approach

Coordinatore	UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN    more  Organization address address: BELFIELD city: DUBLIN postcode: 4 contact info Titolo: Mr. Nome: Donal Cognome: Doolan Email: send email Telefono: +353 1 7161656 Fax: +353 1 7161216
Nazionalità Coordinatore	Ireland [IE]
Totale costo	1˙736˙483 €
EC contributo	1˙736˙483 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-IAPP-2008
Funding Scheme	MC-IAPP
Anno di inizio	2009
Periodo (anno-mese-giorno)	2009-08-01   -   2013-07-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN  Organization address address: BELFIELD city: DUBLIN postcode: 4 contact info Titolo: Mr. Nome: Donal Cognome: Doolan Email: send email Telefono: +353 1 7161656 Fax: +353 1 7161216	IE (DUBLIN)	coordinator	354˙949.00
2	OncoMark Limited  Organization address address: Weston Park 76 city: DUBLIN 14 postcode: - contact info Titolo: Mr. Nome: Stephen Cognome: Penney Email: send email Telefono: -8571533 Fax: -6144769	IE (DUBLIN 14)	participant	794˙659.00
3	CELLIX LIMITED  Organization address address: LONG MILE ROAD UNIT 1 city: Dublin postcode: 12 contact info Titolo: Ms. Nome: Vivienne Cognome: Williams Email: send email Telefono: 35318963182 Fax: 35318962771	IE (Dublin)	participant	198˙994.00
4	UPPSALA UNIVERSITET  Organization address address: SANKT OLOFSGATAN 10 B city: UPPSALA postcode: 751 05 contact info Titolo: Prof. Nome: Fredrik Cognome: Ponten Email: send email Telefono: +46 18 6113846 Fax: +46 18 553354	SE (UPPSALA)	participant	198˙849.00
5	FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE  Organization address address: AVENIDA GRAN VIA HOSPITALET 199-203 city: L'HOSPITALET DE LLOBREGAT postcode: 8908 contact info Titolo: Ms. Nome: Victoria Cognome: Cochrane Email: send email Telefono: 34932607374 Fax: 34932607776	ES (L'HOSPITALET DE LLOBREGAT)	participant	121˙875.00
6	UNIVERSITEIT MAASTRICHT  Organization address address: Minderbroedersberg 4-6 city: MAASTRICHT postcode: 6200 MD contact info Titolo: Ms. Nome: Sietske Cognome: Satijn Email: send email Telefono: +31(0)43-3881867 Fax: +31(0)43-3881890	NL (MAASTRICHT)	participant	67˙157.00
7	KATHOLIEKE UNIVERSITEIT LEUVEN  Organization address address: Oude Markt 13 city: LEUVEN postcode: 3000 contact info Titolo: Dr. Nome: Elke Cognome: Lammertyn Email: send email Telefono: +32 16 32 06 21 Fax: +32 16 32 65 15	BE (LEUVEN)	participant	0.00
8	ONCOMETHYLOME BVBA  Organization address address: GASTON GEENLAAN 1 city: LEUVEN postcode: 3001 contact info Titolo: Mr. Nome: Joost Cognome: Louwagie Email: send email Telefono: +32 16751380 Fax: +32 16 751 381	BE (LEUVEN)	participant	0.00
9	SlidePath  Organization address address: "Invent Building, Dublin City University" city: Dublin postcode: 9 contact info Titolo: Ms. Nome: Sinead Cognome: Kilkelly Email: send email Telefono: 00353 1 7007579 Fax: 00353 1 7007555	IE (Dublin)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Transformed melanocytes use several strategies to enable their progression to advanced melanoma and metastasis, including genetic and epigenetic alterations, along with disruptions to gene and protein expression. This consortium aims to identify novel biomarkers for predicting the progression and prognosis of melanoma. To achieve this, a concerted collaborative effort is proposed here between key academic and industrial partners, centred on intersectorial training of experienced researchers. Our first goal is to identify novel methylated genes via several complementary screening methods, followed by validation extensive melanoma cohorts available to the consortium. We will use the following strategies to identify methylated genes: (1) an array-based technique called MeDIP-ON-CHIP, (2) a high-throughput bisulphite-based technique developed by Illumina (to simultaneously analyse up to 800 genes over 96 samples) and (3) in silico analysis of DNA microarray data. To validate these methylation targets, we will use both qualitative and quantitative methylation-specific PCR (MSP) and determine if these methylation events correlate with melanoma progression, i.e. from benign and atypical nevi to primary and metastatic tumours. Our second goal is to validate genes that associate with melanoma progression and prognosis. For this aspect of the project, we will concentrate on the application of tissue microarray technology and associated image analysis approaches to validate molecular determinants of melanoma progression. Prioritised targets will then be functionally validated by a unique in vitro assay that models extravasation, or exit of cancer cells out of the blood stream, a key step in the metastatic process. Overall, these studies will give clues to melanoma progression, and may identify important targets for melanoma treatment. In addition, this industry-academic partnership will provide a valuable cross-disciplinary training ground for emerging researchers.'

Introduzione (Teaser)

Mechanisms of malignant skin cancers